BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sciacqua A, Succurro E, Armentaro G, Miceli S, Pastori D, Rengo G, Sesti G. Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. Heart Fail Rev 2021. [PMID: 34859336 DOI: 10.1007/s10741-021-10182-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Nakai M, Iwanaga Y, Kanaoka K, Sumita Y, Nishioka Y, Myojin T, Kubo S, Okada K, Soeda T, Noda T, Sakata Y, Imamura T, Saito Y, Yasuda S, Miyamoto Y. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society. Cardiovasc Diabetol 2022;21:157. [PMID: 35964039 DOI: 10.1186/s12933-022-01586-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Armentaro G, D’arrigo G, Miceli S, Cassano V, Perticone M, Maio R, Marra AM, Arturi F, Cittadini A, Tripepi G, Sesti G, Sciacqua A. Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study. Front Physiol 2022;13:897109. [DOI: 10.3389/fphys.2022.897109] [Reference Citation Analysis]
3 Turan B, Durak A, Olgar Y, Tuncay E. Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction. Mol Cell Biochem. [DOI: 10.1007/s11010-022-04474-5] [Reference Citation Analysis]
4 Pelaia C, Armentaro G, Volpentesta M, Mancuso L, Miceli S, Caroleo B, Perticone M, Maio R, Arturi F, Imbalzano E, Andreozzi F, Perticone F, Sesti G, Sciacqua A. Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea. Front Cardiovasc Med 2022;9:861663. [PMID: 35449875 DOI: 10.3389/fcvm.2022.861663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ye H, He Y, Zheng C, Wang F, Yang M, Lin J, Xu R, Zhang D. Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway. Front Pharmacol 2022;13:816588. [PMID: 35308248 DOI: 10.3389/fphar.2022.816588] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Daniilopoulou I, Vlachou E, Lambrou GI, Ntikoudi A, Dokoutsidou E, Fasoi G, Govina O, Kavga A, Tsartsalis AN. The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review. Medicina 2022;58:224. [DOI: 10.3390/medicina58020224] [Reference Citation Analysis]
7 Palazzuoli A, Savarese G. An update on diabetes spectrum in heart failure: current evidence and potential therapeutic applications. Heart Fail Rev. [DOI: 10.1007/s10741-021-10202-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]